Home›Trial›NCT05565248
🔬NCT05565248Phase 1Phase 2RECRUITING

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

Study Summary

This is an open-label, multicenter, Phase 1/2 study evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects with T1D

Conditions
Diabetes MellitusDiabetes Mellitus, Type 1Glucose Metabolism DisordersMetabolic DiseaseEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases
Interventions / Drugs
VCTX211
View on ClinicalTrials.gov ↗
Sponsor
CRSP
CRISPR Therapeutics
Gene Editing
D43/100
Study Details
Enrollment40 participants
Primary Completion—
Lead SponsorCRISPR Therapeutics AG
Data Retrieved2026-04-11 04:10:52.768000+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.